Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 20;66(9):e0068922.
doi: 10.1128/aac.00689-22. Epub 2022 Aug 9.

In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria

Affiliations

In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria

Barbara A Brown-Elliott et al. Antimicrob Agents Chemother. .

Erratum in

Abstract

Nontuberculous mycobacteria (NTM) infections are increasing worldwide. Mycobacterium avium complex (MAC) and the M. abscessus species are the most commonly cultured NTM and treatment options are limited, especially for the M. abscessus species. In this study, the in vitro activity of eravacycline, a new tetracycline derivative, was tested against 110 clinical isolates of NTM. MIC testing was performed as recommended by the Clinical and Laboratory Standards Institute against 60 isolates of rapidly growing mycobacteria (RGM), of which ~70% were tetracycline resistant. These included M. abscessus subsp. abscessus (8 isolates), M. abscessus subsp. massiliense (5), M. chelonae (10), M. immunogenum (3), M. fortuitum group (20) including 12 doxycycline-resistant isolates, and M. mucogenicum group (10) including three doxycycline-resistant isolates. Due to trailing, eravacycline MICs were read at 80% and 100% inhibition. Eravacycline was active against all RGM species, with MIC50 ranges of ≤0.015 to 0.5 and ≤0.015 to 0.12 μg/mL for 100% and 80% inhibition, respectively. For M. abscessus subsp. abscessus, MIC50 values were 0.12 and 0.03 μg/mL with 100% and 80% inhibition, respectively. MICs for tigecycline were generally within 1 to 2 dilutions of the 100%-inhibition eravacycline MIC values. Fifty isolates of slowly growing mycobacteria (SGM) species, including 16 isolates of MAC, were also tested. While there was no trailing observed in most SGM, the eravacycline MICs were higher (MIC range of >8 μg/mL), except for M. kansasii and M. marinum which had MIC50 values of 1 μg/mL. This study supports further evaluation of eravacycline, including clinical trials for the development of RGM treatment regimens, especially for M. abscessus.

Keywords: eravacycline; nontuberculous mycobacteria; susceptibility.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. The authors received partial funding for this study from Tetraphase Pharmaceuticals Inc.

Figures

FIG 1
FIG 1
Eravacycline MICs show a trailing pattern similar to that of omadacycline, which is shown in this graphic representation. The wells in which 80% and 100% inhibition were read are indicated with arrows. (Reproduced from previous work [22]).
FIG 2
FIG 2
Eravacycline MICs show a trailing pattern similar to that of omadacycline, which is shown in this photograph (no photographs of eravacycline wells were available). (Reproduced from previous work [22]).

Similar articles

Cited by

References

    1. Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. 2019. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis 13:e0007083. 10.1371/journal.pntd.0007083. - DOI - PMC - PubMed
    1. Brode SK, Marchand-Austin A, Jamieson FB, Marras TK. 2017. Pulmonary versus nonpulmonary nontuberculous mycobacteria, Ontario, Canada. Emerg Infect Dis 23:1898–1901. 10.3201/eid2311.170959. - DOI - PMC - PubMed
    1. Honda JR, Virdi R, Chan ED. 2018. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. Front Microbiol 9:2029. 10.3389/fmicb.2018.02029. - DOI - PMC - PubMed
    1. Rivero-Lezcano OM, González-Cortés C, Mirsaeidi M. 2019. The unexplained increase of nontuberculous mycobacteriosis. Int J Mycobacteriol 8:1–6. 10.4103/ijmy.ijmy_18_19. - DOI - PubMed
    1. Prevots DR, Marras TK. 2015. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a Review. Clin Chest Med 36:13–34. 10.1016/j.ccm.2014.10.002. - DOI - PMC - PubMed

Publication types

MeSH terms